NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting
– Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy
– NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 treatment related events as of May 2023
Related news for (NEXI)
- NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting